Skip to main content
Fig. 2 | Acta Neuropathologica Communications

Fig. 2

From: A tumor suppressor role for EZH2 in diffuse midline glioma pathogenesis

Fig. 2

a Schematic representation to show establishment of the EZH2 overexpression DMG mouse model. b. Representative H&E images from EZH2 WT and EZH2 GOF mice (top), scale bar = 500 µm and (bottom) Kaplan–Meier survival curves of mice from both the groups (p < 0.0001, log-rank test). c. Representative Ki-67 IHC staining from EZH2 WT and EZH2 GOF tumors and quantitation of staining (p < 0.001, unpaired t-test n = 3 tumors/group), scale bar = 50 µm d. Representative H3K27me3 staining in EZH2 WT and EZH2 GOF tumors, quantitation of H3K27me3 staining (p = 0.03, paired t-test n = 3 tumors/group) and immunoblot detection of H3K27me3, H3 (loading control) in histone extracts of tumors and EZH2 and Lamin B1 (loading control) from whole cell extracts of tumors from EZH2 WT and EZH2 GOF mice, scale bar 2 µm e. Tumor incidence comparison between EZH2 WT and EZH2 GOF mice (p < 0.001, Fisher’s exact test). f. Tumor grades across the EZH2 WT and EZH2 GOF mice were determined as described. g. Cell proliferation BrdU ELISA assay of neuronal precursor cells from Ntv-a;Ezh2Y641F/+ P3 pups infected with RCAS-PDGF-B, RCAS-shp53-RFP and RCAS-Y/RCAS-CRE viruses and treated with EZH2 inhibitor, EPZ011989 (p < 0.05, unpaired t-test, n = 3 independent experiments)

Back to article page